Twilight Litaka Pharma Peer Comparison

NSE: TWILITAKA | BSE: 506985

₹2.88

₹-0.15 (-4.95%)

As on 01-Jan-2015IST

Market cap

₹7 Cr

Revenue (TTM)

₹13 Cr

P/E Ratio

P/B Ratio

-0

Div. Yield

0 %

Edit

	Twilight Litaka Pharma	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Market cap (₹ Cr)	7	35,540	27,486	26,303	26,308
Revenue (₹ Cr)	13	3,564	9,205	1,936	1,462
Net Profit (₹ Cr)	-147.22	414.00	-371.81	288.22	387.35
Net Margin (%)	-1,169.22	11.23	-3.93	14.79	26.01
RoE (%)	--	8.38	-3.85	29.77	25.18
Price to Earnings	--	86.90	--	91.26	68.12
Price-To-Book	-0.05	7.06	3.43	19.60	15.25

Income Statement (₹ Cr)

	Twilight Litaka Pharma	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Operating Revenue	31.50	4,830.36	--	41.58	76.11
Total Income	31.51	4,914.64	--	41.73	76.68
Total Expenditure	40.46	3,850.53	--	30.00	69.99
EBITDA	-8.95	979.83	--	11.59	6.12
Depreciation	5.39	139.92	--	3.35	0.80
EBIT	-14.34	839.91	--	8.24	5.32
Interest	0.41	83.35	--	2.34	1.58
Other Income	0.00	84.28	--	0.14	0.56
Exceptional Items	-125.45	49.83	--	--	--
Profit before Tax	-140.20	890.67	--	6.04	4.31
Provision for Tax	1.17	47.88	--	1.54	1.44
Profit after Tax	-140.20	842.79	--	4.50	2.86

	Twilight Litaka Pharma	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Shareholder's Funds	-132.30	3,581.47	--	44.83	10.77
Minority Interest	--	136.17	--	--	--
Non-Current Liabilities	39.25	1,161.18	--	10.36	1.29
Current Liabilities	424.39	1,743.20	--	21.34	26.33
Total Liabilities	331.35	6,622.02	--	76.53	38.71

	Twilight Litaka Pharma	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Non-Current Assets	112.86	3,266.10	--	51.75	7.38
Current Assets	218.48	3,355.92	--	24.78	31.01
Total Assets	331.35	6,622.02	--	76.53	38.71
Total Debt*	321.98	1,906.08	--	21.09	12.17
Net Current Assets	-205.91	1,612.72	--	3.44	4.68
Contingent Liabilities	107.19	267.40	--	4.70	--

	Twilight Litaka Pharma	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Cash From Operating Activities	1.52	1,476.29	--	6.29	-0.21
Cash Flow from Investing Activities	-0.36	-851.62	--	-5.46	-2.00
Cash from Financing Activities	-0.66	-601.32	--	-0.58	2.17
Net Cash Inflow / Outflow	0.50	23.35	--	0.25	-0.04

	Twilight Litaka Pharma	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
ROCE (%)	-55.00	18.98	--	13.38	29.97
ROE (%)	0.00	30.04	--	19.08	30.26
ROA (%)	-35.44	13.36	--	6.16	8.85
EBIT Margin (%)	-28.41	22.03	--	28.21	8.78
Net Margin (%)	-444.96	17.15	--	10.78	3.74
Cash Profit Margin (%)	-427.90	20.32	--	18.86	4.81

	Twilight Litaka Pharma	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Revenue Growth (%)	-90.69	-13.89	--	12.11	37.10
EBIT Growth (%)	80.33	-49.66	--	21.82	30.95
Net Profit Growth (%)	17.99	-46.64	--	58.36	39.55
EPS Growth (%)	17.99	-56.04	--	58.36	39.55
Book Value Growth (%)	-6,435.70	36.37	--	21.09	32.03

	Twilight Litaka Pharma	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Price / Earnings	0.00	6.59	--	0.00	0.00
Price / Book Value	-0.11	1.55	--	0.00	0.00
Dividend Yield (%)	0.00	2.19	--	--	--
EV/EBITDA	-37.56	5.73	--	3.52	2.02
Market Cap (₹ Cr)	15.09	5,016.58	--	0.00	0.00

	Twilight Litaka Pharma	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Debt to Equity	-2.33	0.54	--	0.47	1.13
Short term debt to equity ratio	-1.84	0.06	--	0.23	0.84
Current Ratio	0.51	1.93	--	1.16	1.18
Quick Ratio	0.51	1.36	--	1.11	0.75
Interest Coverage	-341.46	11.69	--	3.58	3.73

	Twilight Litaka Pharma	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Debtors to sales (%)	663.25	9.96	--	33.85	17.81
Asset Turnover	0.08	0.77	--	0.57	2.35
Receivable days	2,740.44	54.33	--	106.93	58.46
Inventory Days	342.60	77.43	--	10.49	41.85
Payable days	569.97	120.43	--	213.33	91.25
Cash Conversion Cycle	2,513.07	11.32	--	-95.91	9.06

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.